Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy : ML18147 study KRAS subgroup findings

Autor: S. Kubicka, R. Greil, T. André, J. Bennouna, J. Sastre, E. Van Cutsem, R. von Moos, P. Österlund, I. Reyes-Rivera, T. Müller, M. Makrutzki, D. Arnold, J. Andel, P. Balcke, B. Benedicic, W. Eisterer, M. Fridrik, B. Jagdt, F. Keil, A. Kretschmer, P. Krippl, H. Oexle, M. Pecherstorfer, H. Samonigg, M. Schmid, J. Thaler, C. Tinchon, H. Weiss, J. Arts, M. De Man, G. Demolin, J. Janssens, M. Polus, B. Benczikova, B. Melichar, J. Prausova, P. Vitek, F.Z. Andersen, B.B. Jensen, N. Keldsen, K. Østerlind, K. Vistisen, A. Elme, A. Magi, K. Ojamaa, R. Ristamäki, T. Salminen, M. Ben Abdelghani, O. Bouche, C. Borg, K. Bouhier-Leporrier, G. Breysacher, L. Chone, M.-C. Clavero Fabri, G. Deplanque, F. Desseigne, L.-M. Dourthe, J. Ezenfis, R. Faroux, E. François, C. Garnier, M.-H. Gaspard, M. Hebbar, J.F. Illory, M.-C. Kaminsky, T. Lecomte, J.-L. Legoux, B. Levache, C. Lobry, J.-P. Lotz, M. Mabro, S. Manet-Lacombe, S. Manfredi, T. Matysiak Budnik, L. Miglianico, L. Mineur, I. Moullet, H. Naman, P. Nouyrigat, S. Oziel-Taieb, H. Perrier, D. Pezet, J. Philip, V. Pottier, M. Porneuf, M. Ramdani, D. Re, Y. Rinaldi, D. Spaeth, J. Taieb, E. Terrebonne, P. Texereau, A. Thirot Bidault, C. Tournigand, N. Tubiana-Mathieu, J.-M. Vantelon, F. Viret, M. Ychou, M. Bangerter, M.E. Bertram, B. Bohnsteen, L. Brinkmann, K. Caca, C. Constantin, H.-J. Cordes, G. Dietrich, J. Eggert, E. Engel, J. Fahlke, H. Fensterer, A. Florschütz, G. Folprecht, H. Forstbauer, W. Freier, M. Freund, N. Frickhofen, E. Gäbele, M. Geißler, F. Gieseler, T. Göhler, U. Graeven, M. Groschek, M. Grundeis, U. Hacker, V. Hagen, H.F. Hebart, S. Hegewisch-Becker, M. Heike, T. Herrmann, B. Hildebrandt, H.-G. Höffkes, G. Hübner, J. Hübner, E. Kettner, M. Kneba, J.W. Kohnke, G. Kojouharoff, C. König, A. Kretzschmar, H. Kröning, K. Kürner, F. Lammert, C. Lerchenmüller, A. Lück, J. Meiler, H.-G. Mergenthaler, L. Müller, C. Müller-Naendrup, A. Nusch, J. Papke, R. Porschen, J. Rädle, C. Reddemann, K. Ridwelski, J. Riera-Knorrenschild, J. Rudi, A. Schmalenberger, C.-C. Schimanski, F. Schlegel, C. Schlichting, P. Schmidt, W. Schmiegel, S. Schmitz, H. Schulze-Bergkamen, I. Schwaner, A. Schwarzer, M. Schwerdtfeger, J. Selbach, M. Sieber, J. Siebler, P. Staib, M. Stauch, C.-C. Steffens, P. Stübs, J. Tischendorf, T. Trarbach, D. Tummes, A.-R. Valdix, A. Vogel, G.P.L. Von Wichert, M. Walther, W. Welslau, G. Wilhelm, H. Wobster, T. Wolf, N. Zeigenhagen, B. Zomorodbaksch, E. Batman, H.J. Bloemendal, D.F.S. Kehrer, T. Guren, G. Indrebø, C. Kersten, H. Soerbye, M. Fragoso, R. Fragoso, J.C. Mellidez, A. Sa, A. Aljobran, T. Darwish, V. Alonso-Orduna, J. Aparicio, E. Aranda, C. Bosch, A. Galan-Brotons, I. Busquier Hernandez, J.C. Camara, J.M. Campos Cervera, C. Carlos Garcia Giron, P.M. Del Prado, O. Donnay, P. Escudero, E. Falco, J. Gallego Plazas, P. Garcia Alfonso, E. Gonzalez Flores, C. Gravalos, R. Guardeno, A. Juárez, A. Lopez Ladron, F. Losa Gaspa, J. MªVicent Vergé, E. Marcuello Gaspar, B. Massuti Sureda, J. Molina, I.C. Montero, A.L. Muñoa, M.B. Naranjo, M.J. Oruezabal Moreno, V. Pachón Olmos, C. Pericay, J.J. Reina Zoilo, F. Rivera, A. Ruiz Casado, M.J. Safont, A. Salud Salvia, M. Tobena, J.C. Toral, V. Valenti, M. Valladares Ayerbes, J.M. Vieitez, R. Vera, A. Berglund, E. Fernebro, V. Hess-Umbricht, M. Pless, R. Popescu, R. Winterhalder

ML18147 evaluated continued bevacizumab with second-line chemotherapy for patients with metastatic colorectal cancer (mCRC) progressing after the standard first-line bevacizumab-containing therapy.Evaluating outcomes according to tumor Kirsten rat sa

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c523a56f9351b43c7684d54c3124cffe
https://www.ncbi.nlm.nih.gov/pubmed/23852309

Bevacizumab plus chemotherapy continued beyond first progression in patients with metastatic colorectal cancer previously treated with bevacizumab plus chemotherapy: ML18147 study KRAS subgroup findings.

Autor: Kubicka S; Cancer Center Reutlingen, Reutlingen, Germany. kubicka_s@klin-rt.de, Greil R, André T, Bennouna J, Sastre J, Van Cutsem E, von Moos R, Osterlund P, Reyes-Rivera I, Müller T, Makrutzki M, Arnold D

Publikováno v: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2013 Sep; Vol. 24 (9), pp. 2342-9. Date of Electronic Publication: 2013 Jul 12.